4d
Medpage Today on MSNStudies Point to Several Options for Ulcerative Colitis After Anti-TNF FailureSAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...
For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...
Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...
Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...
As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance provisions of the Competition Act (the Act), relating to ustekinumab (Janssen ...
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...
and Ustekinumab in autoimmune therapy. Biocon Biologics Ltd expects a significant rise in demand for its insulin products across geographies in the coming months and years, managing director and ...
UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...
Dong-A Socio Holdings posts 82.1 billion won profit, sales rise to 1.33 trillion won Dong-A Socio Holdings achieves ...
Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune <a target=_blank h ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results